Analyst Ratings For Kala Pharmaceuticals Inc (NASDAQ:KALA)
Today, HC Wainwright reiterated its Buy rating on Kala Pharmaceuticals Inc (NASDAQ:KALA).
There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Kala Pharmaceuticals Inc (NASDAQ:KALA) is Buy with a consensus target price of $25.75 per share, a potential 459.78% upside.
Some recent analyst ratings include
- 12/27/2018-Kala Pharmaceuticals Inc (NASDAQ:KALA) had its Buy rating reiterated by HC Wainwright
- 10/4/2018-Kala Pharmaceuticals Inc (NASDAQ:KALA) had its Buy rating reiterated by Wells Fargo & Co with a $15.00 price target
- 8/15/2017-Kala Pharmaceuticals Inc (NASDAQ:KALA) has coverage initiated with a Outperform ➝ Outperform rating and $46.00 price target
- 8/14/2017-Kala Pharmaceuticals Inc (NASDAQ:KALA) has coverage initiated with a Buy ➝ Buy rating and $33.00 price target
- On 10/5/2018 Gregory Grunberg, Director, bought 606,060 with an average share price of $8.25 per share and the total transaction amounting to $4,999,995.00.
- On 10/3/2018 Ra Capital Healthcare Fund Lp, Director, bought 2,424,242 with an average share price of $8.25 per share and the total transaction amounting to $19,999,996.50.
- On 2/8/2018 Orbimed Advisors Llc, Major Shareholder, bought 25,000 with an average share price of $12.93 per share and the total transaction amounting to $323,250.00.
- On 2/1/2018 Orbimed Advisors Llc, Major Shareholder, bought 362,240 with an average share price of $15.00 per share and the total transaction amounting to $5,433,600.00.
- On 1/29/2018 Orbimed Advisors Llc, Major Shareholder, bought 72,760 with an average share price of $14.97 per share and the total transaction amounting to $1,089,217.20.
- On 1/26/2018 Orbimed Advisors Llc, Major Shareholder, bought 22,760 with an average share price of $14.93 per share and the total transaction amounting to $339,806.80.
- On 1/24/2018 Orbimed Advisors Llc, Major Shareholder, bought 64,637 with an average share price of $14.91 per share and the total transaction amounting to $963,737.67.
About Kala Pharmaceuticals Inc (NASDAQ:KALA)
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Recent Trading Activity for Kala Pharmaceuticals Inc (NASDAQ:KALA)
Shares of Kala Pharmaceuticals Inc closed the previous trading session at 4.60 0.00 0.00% with 4.86 shares trading hands.
